What researchers have measured
Published work has examined tissue healing, inflammatory signaling, pharmacokinetics, pain reports, and small safety samples. These are study endpoints, not a validated clinical monitoring framework.
The evidence gap
- No large controlled human dose-ranging program.
- No established reference changes tied to exposure.
- No validated long-term safety surveillance protocol.
What this evidence review covers
Explain that measurements in a two-person pilot do not create a BPC-157 monitoring panel.
- What the pilot measured
- Why safety observations differ from validated monitoring
- Preclinical biomarkers are not clinical orders
- No five-lab checklist
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
direct human evidence
The pilot collected short-term laboratory and vital-sign observations in only two people.
regulatory
FDA says safety information is insufficient for the proposed routes.
| Evidence class | What the source supports |
|---|---|
| direct human evidence | The pilot collected short-term laboratory and vital-sign observations in only two people. |
| regulatory | FDA says safety information is insufficient for the proposed routes. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Evidence class: primary uncontrolled human pilot. What it supports: Two previously exposed adults; short-term vital-sign and laboratory observations; no efficacy endpoint.
What it does not establish: General safety, any efficacy claim, a dosage schedule, a monitoring protocol, or other routes.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Questions this page answers
Which labs should be tracked?
The source does not validate a personal monitoring panel; report only what investigators measured and the n=2 limitation.
Do normal labs prove safety?
No. Normal short-term measurements in two participants cannot rule out other harms.
What remains unresolved
- No validated monitoring protocol.
- No target values or schedule.
- No efficacy biomarkers established.